Skyhawk Therapeutics Unveils Promising Results from SKY-0515 Study for Huntington's Disease

Skyhawk Therapeutics Reveals Promising Results from SKY-0515 Study

In a groundbreaking disclosure, Skyhawk Therapeutics has announced the results of its twelve-month clinical trial evaluating SKY-0515, a novel small molecule therapy designed for Huntington's Disease (HD). The study, classified as a Phase 1/2 clinical trial, provides robust evidence of the drug's effectiveness by showing significant and consistent trends across all four components of the composite Unified Huntington's Disease Rating Scale (cUHDRS) — namely, Total Functional Capacity (TFC), Total Motor Score (TMS), the Symbol Digit Modalities Test (SDMT), and the Stroop Word Reading Test (SWRT).

Positive Trends Observed in Patients

After twelve months of treatment, patients receiving SKY-0515 exhibited an unexpected positive average change in the TFC score of +0.07, while the anticipated decline based on past data suggested -0.87 points. Similarly, the data for the TMS indicated a beneficial change contrasting the forecasted deterioration of -2.00 with a measured expectation of -2.21 from prior analyses. Furthermore, participants showed a favorable stability in SDMT scores, maintaining a relatively stable position against an expected drop of -1.78 points. The SWRT reported a remarkable average improvement of +3.44 compared to a predicted decline of -3.13 points.

This improvement in motor and cognitive functionality supports the belief that SKY-0515 can bring about significant positive changes in the lives of those afflicted with Huntington's Disease.

Clinician and Patient Perspectives

Adding weight to these findings, the company shared preliminary data from physician and patient surveys that assessed perceptions of disease progression. Surprisingly, neither the physicians nor the patients noted any deterioration in condition. Approximately 65% of the participants reported an observable improvement, while 50% of healthcare providers echoed this sentiment, a promising outcome considering Huntington's typically predictable decline.

"We are excited to present these significant partial results from our cUHDRS evaluations, including TFC and TMS data on functional and motor performance, as well as cognitive test results from SDMT and SWRT," stated Sergey Paushkin, head of research and development at Skyhawk Therapeutics.

Marked Reduction of Mutated Proteins

Moreover, SKY-0515 demonstrated a dose-dependent reduction in the levels of mutant huntingtin protein (mHTT) in the bloodstream by up to 69%. There was also a decrease of up to 26% in PMS1 mRNA, the latter being a key trigger associated with disease progression. These biomarkers are crucial, as mHTT plays a significant role in the pathology of Huntington's Disease, and PMS1 is closely linked to the somatic CAG repeat expansion that exacerbates the condition.

The results from this trial provide a foundation for further exploration into the therapeutic potential of SKY-0515, heralding a possible new pathway for treatment options for patients enduring the relentless impacts of Huntington's Disease.

Skyhawk continues to showcase the potential of its proprietary SKYSTAR® platform, with plans to develop additional innovative therapies for other rare neurological disorders without approved disease-modifying treatments. The company envisions introducing further clinical development programs by the end of 2027.

Conclusion

The significance of the findings could not be overstated — with more than 40,000 people in the United States suffering from HD alone and hundreds of thousands affected globally, the advent of SKY-0515 could represent a monumental shift in the landscape of available treatment. The lack of approved medications to slow or halt the progression of this devastating illness underscores the urgency of such advancements in the field. As Skyhawk Therapeutics moves forward, they remain hopeful that the persistent efficacy of SKY-0515 can provide the long-awaited therapeutic relief that Huntington's Disease patients deserve, potentially revolutionizing care in this challenging domain.